Deadline
Passed
Lead Plaintiff Deadline: January 18, 2022
(1) Owlet was reasonably likely to be required to obtain marketing authorization for the Smart Sock because the Food and Drug Administration concluded it was a medical device; (2) as a result, Owlet was reasonably likely to cease commercial distribution of the Smart Sock in the U.S. until it obtained the requisite approval; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.